Final approval of the vaccine Pfizer/BioNTech for COVID-19 is expected to be given in September by the American Drug Administration (FDA), as the New York Times wrote on Tuesday.
According to the newspaper, which cites informed sources, the “official date” that this preparation is expected to receive a final green light from the FDA is September 6, but it is possible that full approval will be given even “earlier”.
At this stage, the US pharmaceutical industry is delivering the vaccine developed in collaboration with the German Biotechnology Laboratory thanks to the emergency license issued on December 11, 2020.
According to the Athenian-Macedonian News Agency, last week, the FDA said in a press release that the process of approving this vaccine for COVID-19 is “among the highest priorities” of the service and that it was to receive its decision before the informal deadline, which is September 6.
Fully licensing the drug could boost confidence and push more Americans to get vaccinated, while the Delta variant, much more contagious than the original SARS-CoV-2 strain, is causing a further increase in the number of infections in the United States. country.
Some 192 million Americans have received at least one dose of one of the approved ones vaccines for COVID-19, in other words 58% of the population or 70% of adults.
However, on July 27, according to the Federal Centers for Disease Control and Prevention (CDC), cases of the new coronavirus reached 66,000 on a daily basis, which is six times more than in June.
Moderna, the company that produces the second most widely used vaccine in the country, also under an emergency license, also in turn, shortly afterwards, applied for full approval.
Johnson & Johnson, a single-dose vaccine, has not yet applied for it, according to the New York Times.
US President Joe Biden said last week that he expects the FDA to announce its decision on the Pfizer / BioNTech vaccine in the early fall.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
